Last December, the US Food and Drug Administration issued a public Drug Safety Communication about results from a large study conducted in France – the Santé Adulte GH Enfant, or SAGhE, study – which found an increased risk for death with biosynthetic human growth hormone therapy relative to the general French population.  There were 93 deaths in the treated group, compared with the 70 expected from a statistical calculation.
Pourtant, même les organismes professionnels de régulation, censés en être conscients, s’égarent parfois dans ce genre de malentendu et réagissent de manière excessive.